Survival prognostic factors in unresectable/advanced primary thoracic sarcomas

Journal of Thoracic Disease

article

Jerónimo R. Rodriguez-Cid¹  Juan J. Juarez-Vignon Whaley¹  Gisela Sánchez-Domínguez¹  Jordi Guzmán-Casta¹  Sonia Carrasco-CaraChards¹  Jorge A. Alatorre-Alexander¹  Luis M. Martínez-Barrera¹  Carla P. Sánchez-Rios¹  Rodrigo R. Flores-Mariñelarena²  Alec Seidman-Sorsby¹  Mayte Cruz-Zermeño¹  Ivan J. Rodríguez-Zea¹  Patricio J. Santillan-Doherty¹ 

[1] Department of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias . Mexico City;Oncology Center;Health Sciences Research Center, Universidad Anáhuac Mexico

关键词: Primary thoracic sarcomas (PTS);    thoracic oncology;    prognostic factors;    progression-free survival (PFS);    overall survival (OS);   

DOI  :  10.21037/jtd-22-472

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

Background: Primary thoracic sarcomas (PTS) including primary pulmonary and chest wall sarcomas (CWS), are aggressive lung malignancies with limited information specially in an advanced/unresectable setting. Unfortunately, prognostic factors for these malignancies are not well identified. Methods: Retrospective cohort analysis of patients diagnosed with unresectable/advanced soft tissue PTS from a third level reference institute. Univariate and multivariate analysis performed via Cox-regression model. Progression-free survival (PFS) and overall survival (OS) analysis via Kaplan-Meier method. Results: A total of 157 patients were identified, 55.4% female, mean age 51.8 years (range, 18–90 years), 19.1% tobacco exposure and 10.8% asbestos exposure. The most common performance status was Eastern Cooperative Oncology Group (ECOG) 1 (38.9%), most common clinical presentation cough (58.4%) and thoracic pain (55.4%). Undifferentiated sarcoma (37.6%) followed by synovial sarcoma (34.4%) were the most common histologies. Most patients received five chemotherapeutic cycles (37.6%), 57.3% of patients obtained a partial response and 61.1% an overall response rate (ORR). Median PFS was 9 months [95% confidence interval (CI): 8.717–9.283 months]. The multivariable analysis identified ECOG ≥2, a poorer response to chemotherapy (less number of chemotherapy cycles) and an increase Response Evaluation Criteria in Solid Tumors (RECIST) to be associated with a shorter progression-free period. Median OS was 11 months (95% CI: 10.402–11.958 months) with an ECOG ≥2 and a poorer response to chemotherapy (less number of chemotherapy cycles) associated with a shorter survival. Conclusions: Age, gender, comorbidities, tobacco and asbestos exposure, clinical presentation and histopathological diagnosis are not useful prognostic factors in unresectable/advanced PTS, however, an adequate initial ECOG, RECIST and a better response to chemotherapy should be used as prognostic factors in the management of these tumors.

【 授权许可】

Unknown